U.S. patent number 3,789,119 [Application Number 05/149,072] was granted by the patent office on 1974-01-29 for stabilized molded sublingual nitroglycerin tablets.
This patent grant is currently assigned to Parke, Davis & Company. Invention is credited to Salvatore A. Fusari, Leslie M. Lueck.
United States Patent |
3,789,119 |
Fusari , et al. |
January 29, 1974 |
STABILIZED MOLDED SUBLINGUAL NITROGLYCERIN TABLETS
Abstract
Pharmaceutical compositions containing minor proportions of
nitroglycerin and a non-volatile, water-soluble solvent in
combination with a major proportion of a solid, water-soluble
pharmaceutical carrier. Those compositions, in the form of tablets
suitable for sublingual administration, can be produced by wetting
a substantially dry mixture of the nitroglycerin and the solid,
water-soluble pharmaceutical carrier with a solvent mixture
containing a non-volatile, water-soluble solvent and a volatile
solvent, forming the wetted mixture into tablets, and removing the
volatile solvent.
Inventors: |
Fusari; Salvatore A. (St. Clair
Shores, MI), Lueck; Leslie M. (Oxford, MI) |
Assignee: |
Parke, Davis & Company
(Detroit, MI)
|
Family
ID: |
22528688 |
Appl.
No.: |
05/149,072 |
Filed: |
June 1, 1971 |
Current U.S.
Class: |
514/777; 264/117;
514/772.7 |
Current CPC
Class: |
A61K
9/006 (20130101); A61K 31/21 (20130101); A61K
9/2018 (20130101); A61K 9/2013 (20130101) |
Current International
Class: |
A61K
9/00 (20060101); A61K 31/21 (20060101); A61K
9/20 (20060101); A61k 027/12 () |
Field of
Search: |
;424/349,361,78,298,358 |
References Cited
[Referenced By]
U.S. Patent Documents
Other References
stephenson et al., J. Pharm. Pharma Col(3): 767-776 (1951) "Tablets
of Glycoryl Trinitrate".
|
Primary Examiner: Rose; Shep K.
Attorney, Agent or Firm: Adams; Robert R. Ehrlinger; David
B. Richards; George M. Gall; Edward J.
Claims
We claim:
1. A pharmaceutical molded tablet composition for sublingual
administration consisting essentially of
a. one part by weight of nitroglycerin,
b. 0.5 to 0.9 parts by weight of a non-volatile, water-soluble
solvent selected from the group consisting of polyethylene glycols
having an average molecular weight in the range of 300 to 7,500,
tetramethylene glycol, and pentamethylene glycol, and
c. 20 to 200 parts by weight of a solid, water-soluble
pharmaceutical carrier of the class consisting of lactose, glucose,
sucrose, mannitol, and sorbitol,
said molded sublingual tablet composition being capable of giving a
rapid release of nitroglycerin upon sublingual administration, and
being thereby stabilized against the tendency of nitroglycerin to
otherwise migrate significantly from tablet to tablet, from tablet
to environment, and from tablet to container stuffing capable of
absorbing nitroglycerin in sealed or imperfectly sealed containers
with resulting loss of original potency during storage.
2. A pharmaceutical composition according to claim 1 wherein the
non-volatile, water-soluble solvent is a polyethylene glycol having
an average molecular weight of 300 to 1,000.
3. A pharmaceutical composition according to claim 1 wherein the
solid, water-soluble pharmaceutical carrier is substantially a
mixture of lactose and sucrose.
4. A pharmaceutical composition according to claim 1 in the form of
tablets containing 0.1 to 1.0 mg. of nitroglycerin per tablet.
Description
SUMMARY AND DETAILED DESCRIPTION
The present invention relates to new and improved pharmaceutical
compositions of nitroglycerin, and to methods for producing those
compositions.
Nitroglycerin (glyceryl trinitrate) is widely used in medical
practice as a coronary vasodilator. It is normally used in the form
of tablets for sublingual administration containing approximately
0.2 to 0.65 mg. of nitroglycerin per tablet. Nitroglycerin tablets
are administered for the purpose of producing a rapid coronary
vasodilator effect relieving acute attacks of angina pectoris, and
thus it is important that they retain the correct potency in terms
of the active ingredient and that the active ingredient be promptly
released for absorption upon sublingual administration.
It is known that nitroglycerin tablets that meet accepted standards
of potency and uniformity at the time of manufacture may fail to
meet those standards of potency and uniformity following storage
over a period of only a few months or less.
In accordance with the present invention, it has been found that
the failure of nitroglycerin tablets to maintain satisfactory
potency and uniformity upon storage can be attributed to a
migration of nitroglycerin from tablet to tablet and from the
tablets to the environment. It has been found that the migration of
nitroglycerin from the tablets to the environment is especially
significant when the container is not tightly sealed so that the
nitroglycerin can volatilize from the tablets through the loose
seal into the atmosphere. It has also been found that the migration
of nitroglycerin from the tablets to the environment is especially
significant when the container has rayon or cotton stuffing
material whereby nitroglycerin is volatilized from the tablets and
absorbed on the stuffing material. However, in accordance with the
invention, migration of nitroglycerin from tablet to tablet with
resulting loss of uniformity has been found to occur even in sealed
glass containers without rayon or cotton stuffing material. The
lack of uniformity can be demonstrated by the fact that after
storage some tablets have abnormally high potency and some tablets
have abnormally low potency, even though the average potency may
remain within acceptable limits.
It is an object of the present invention to provide pharmaceutical
formulations of nitroglycerin that retain an acceptable level of
potency even in an imperfectly sealed container and in the presence
of rayon, cotton, or other material capable of absorbing
nitroglycerin.
Another object of the invention is to provide pharmaceutical
formulations of nitroglycerin in the form of sublingual tablets
which do not undergo a significant degree of migration of
nitroglycerin from tablet to tablet within the same container.
A further object of the invention is to provide pharmaceutical
formulations of nitroglycerin in the form of sublingual tablets
which retain their original potency without significant deviation
over a long period of storage.
Still a further object of the invention is to provide
pharmaceutical formulations of nitroglycerin in the form of
sublingual tablets having the improved potency retention mentioned
above and having in addition the characteristic of giving rapid
release of nitroglycerin upon sublingual administration.
Yet another object of the invention is to provide methods for
producing the above-mentioned pharmaceutical compositions.
These as well as other objects which will appear hereinafter are
achieved by the new pharmaceutical compositions and methods for
producing them as described below.
In accordance with the invention, new pharmaceutical compositions
of nitroglycerin are prepared to contain in finished form (a) one
part by weight of nitroglycerin, in combination with (b) 0.1 to 4
parts by weight of a non-volatile, water-soluble solvent, and (c)
20 to 200 parts by weight of a solid, water-soluble pharmaceutical
carrier. The term "non-volatile" is used herein in a relative sense
to designate a solvent that when incorporated in the finished
formulation volatilizes to no more than a minor extent over a
period of several months at ordinary temperatures and under
ordinary conditions of storage. That solvent can be a high boiling
liquid or a high boiling, low melting solid that exhibits the
required solvent characteristics under the conditions of use. It
should have a relatively high solubility for nitroglycerin. Some
examples of such solvents are polyethylene glycols, tetramethylene
glycol, and pentamethylene glycol. Preferred solvents are
polyethylene glycols having an average molecular weight in the
range of 300 to 7,500, especially 300 to 1,000. A preferred ratio
of ingredients is one part by weight of nitroglycerin to 0.5 to 0.9
parts by weight of the non-volatile, water-soluble solvent. The
solid, water-soluble pharmaceutical carrier is a sugar or a sugar
derivative such as lactose, glucose, sucrose, mannitol, or
sorbitol. The solid, water-soluble pharmaceutical carrier is used
in an amount, within the proportions indicated above, to impart to
the finished formulation the desired solid state under normal as
well as extreme temperature conditions of storage and use. The new
pharmaceutical formulations of nitroglycerin, as described above,
are desirably provided as tablets suitable for sublingual
administration and containing 0.1 to 1.0 mg., preferably 0.2 to
0.65 mg., of nitroglycerin per tablet. However, if desired, they
can also be provided in other conventional pharmaceutical forms
such as granules.
Also in accordance with the invention, pharmaceutical compositions
of nitroglycerin in the form of tablets for sublingual
administration are produced by the process which comprises (a)
preparing a substantially dry mixture of one part by weight of
nitroglycerin and 20 to 200 parts by weight of a solid,
water-soluble pharmaceutical carrier, (b) wetting that
substantially dry mixture with a solvent mixture containing 0.1 to
4 parts by weight of a non-volatile, water-soluble solvent and a
sufficient quantity of a volatile solvent to permit an even wetting
of the substantially dry mixture by the solvent mixture, (c)
forming the wetted mixture into tablets, and (d) drying the tablets
whereby substantially all of the volatile solvent is volatilized
while substantially all of the non-volatile solvent remains
unvolatilized. The term "non-volatile" is used herein in a relative
sense to designate a solvent that when incorporated in the finished
formulation volatilizes to no more than a minor extent over a
period of several months at ordinary temperatures and under
ordinary conditions of storage. That solvent can be a high boiling
liquid or a high boiling, low melting solid that exhibits the
required solvent characteristics under the conditions of use. It
should have a relatively high solubility for nitroglycerin. Some
examples of such solvents are polyethylene glycols, tetramethylene
glycol, and pentamethylene glycol. Preferred solvents are
polyethylene glycols having an average molecular weight in the
range of 300 to 7,500, especially 300 to 1,000. A preferred ratio
of ingredients is one part by weight of nitroglycerin to 0.5 to 0.9
parts by weight of the non-volatile, water-soluble solvent. The
term "volatile" is used herein in a relative sense to designate a
solvent that readily volatilizes under the conditions normally used
in drying pharmaceutical tablets, for example drying in air at room
temperature for 12 to 48 hours. Such solvents most suitably have a
boiling point of about 100.degree. C. or lower and a preferred
solvent for this purpose is aqueous ethanol or water. The solid,
water-soluble pharmaceutical carrier is a sugar or a sugar
derivative such as lactose, glucose, sucrose, mannitol, or
sorbitol. The solid, water-soluble pharmaceutical carrier is used
in an amount, within the proportions indicated above, to impart to
the finished tablets the desired solid state under normal as well
as extreme temperature conditions of storage and use. The tablets,
as prepared above, are desirably constituted to contain 0.1 to 1.0
mg., preferably 0.2 to 0.65 mg. of nitroglycerin per tablet.
The pharmaceutical compositions described above can, if desired,
also be formulated to contain other ingredients useful in
pharmaceutical compounding.
The pharmaceutical compositions of the invention exhibit the
well-known activity of nitroglycerin in medical practice but show
improved behavior on storage. For example, the sublingual tablets
give a rapid coronary vasodilator effect when dissolved under the
tongue. Additionally, they show improved retention of potency and
uniformity when stored in either glass or plastic containers, with
or without stuffing materials, at temperatures from room
temperature to 45.degree. C., when compared with the behavior of
tablets prepared similarly but without the inclusion of a
non-volatile, water-soluble solvent.
The invention is illustrated by the following examples.
EXAMPLE 1
Ingredient Quantity Nitroglycerin mixture soluble, 6.93 kg. 10%
nitroglycerin Diluent (lactose + sucrose, 44.07 kg. 95:5) Solvent
mixture containing: Ethanol, 95% 3381 ml. Polyethylene glycol 400
520 ml. Purified water 1302 ml.
The nitroglycerin mixture soluble is a product containing 10%
nitroglycerin on .beta.-lactose and the quantity used is seven
percent in excess of the calculated amount.
The diluent contains 95% by weight of the usual lactose of pharmacy
(.alpha.-lactose monohydrate) and 5% by weight of sucrose.
The polyethylene glycol 400 is a polymer of ethylene oxide and
water, represented by the formula H(OCH.sub.2 CH.sub.2).sub.n OH,
in which the average value of n lies between 8.2 and 9.1.
The nitroglycerin mixture soluble is blended with a sufficient
quantity of diluent to produce a siftable mixture. With care, the
siftable mixture is passed through a number 80 mesh silk sieve.
Approximately one-half of the diluent, then the sifted
nitroglycerin and diluent mixture, and then the remainder of the
diluent are added to a blender and thoroughly mixed. While the
blender is operating the solvent mixture is then added and the
ingredients are again blended. The wetted mixture is then formed
into tablets, each weighing approximately 34 mg. after air drying,
on a tablet molding machine. Optimum temperature and humidity
conditions for this operation are a dry bulb temperature of
22.degree. to 26.degree. C. and a dew point temperature of
6.degree. to 9.degree. C. The molded tablets are collected into
trays and air dried at room temperature. Yield equals 1,400,000 to
1,500,000 tablets, each weighing approximately 34 mg. and labeled
to contain 1/150 grain (approximately 0.43 mg.) of nitroglycerin
per tablet; the acceptable variation is an average assay of 90
percent to 11 percent of the indicated potency.
The tablets prepared as described above are suitable for sublingual
administration and exhibit improved behavior on storage when
compared with tablets prepared similarly but without the use of
polyethylene glycol. They maintain acceptable standards of potency
and uniformity upon prolonged storage at room temperature, at
37.degree. C., and at 45.degree. C. The improved behavior on
storage is observed in closed containers as well as in containers
that are opened periodically to simulate conditions of use.
EXAMPLE 2
Ingredient Quantity Nitroglycerin mixture soluble, 10.2 kg. 10%
nitroglycerin Diluent (lactose + sucrose, 40.8 kg. 95:5) Solvent
mixture containing: Ethanol, 95% 3135 ml. Polyethylene glycol 400
765 ml. Purified water 1302 ml.
The nitroglycerin mixture soluble is a product con-taining 10%
nitroglycerin on .beta.-lactose and the quantity used is five
percent in excess of the calculated amount.
The diluent contains 95% by weight of the usual lactose of pharmacy
(.alpha.-lactose monohydrate) and 5% by weight of sucrose.
The polyethylene glycol 400 is a polymer of ethylene oxide and
water, represented by the formula H(OCH.sub.2 CH.sub.2).sub.n OH,
in which the average value of n lies between 8.2 and 9.1.
The nitroglycerin mixture soluble is blended with a sufficient
quantity of diluent to produce a siftable mixture. With care, the
siftable mixture is passed through a number 80 mesh silk sieve.
Approximately one-half of the diluent, then the sifted
nitroglycerin and diluent mixture, and then the remainder of the
diluent are added to a blender and thoroughly mixed. While the
blender is operating the solvent mixture is then added and the
ingredients are again blended. The wetted mixture is then formed
into tablets, each weighing approximately 34 mg. after air drying,
on a tablet molding machine. Optimum temperature and humidity
conditions for this operation are a dry bulb temperature of
22.degree. to 26.degree. C. and a dew point temperature of
6.degree. to 9.degree. C. The molded tablets are collected into
trays and air dried at room temperature. Yield equals 1,400,000 to
1,500,000 tablets, each weighing approximately 34 mg. and labeled
to contain 1/100 grain (approximately 0.65 mg.) of nitroglycerin
per tablet; the acceptable variation is an average assay of 90
percent to 110 percent of the indicated potency.
The tablets prepared as described above are suitable for sublingual
administration and exhibit improved behavior on storage as
described in Example 1.
Example 3
Ingredient Quantity Nitroglycerin mixture soluble, 5.31 kg. 10%
nitroglycerin Diluent (lactose + sucrose, 45.69 kg. 95:5) Solvent
mixture containing: Ethanol, 95% 3502 ml. Polyethylene glycol 400
398 ml. Purified water 1302 ml.
The nitroglycerin mixture soluble is a product containing 10%
nitroglycerin on .beta.-lactose and the quantity used is nine
percent in excess of the calculated amount.
The diluent contains 95% by weight of the usual lactose of pharmacy
(.alpha.-lactose monohydrate) and 5% by weight of sucrose.
The polyethylene glycol 400 is a polymer of ethylene oxide and
water, represented by the formula H(OCH.sub.2 CH.sub.2).sub.n OH,
in which the average value of n lies between 8.2 and 9.1.
The nitroglycerin mixture soluble is blended with a sufficient
quantity of diluent to produce a siftable mixture. With care, the
siftable mixture is passed through a number 80 mesh silk sieve.
Approximately one-half of the diluent, then the sifted
nitroglycerin and diluent mixture, and then the remainder of the
diluent are added to a blender and thoroughly mixed. While the
blender is operating the solvent mixture is then added and the
ingredients are again blended. The wetted mixture is then formed
into tablets, each weighing approximately 34 mg. after air drying,
on a tablet molding machine. Optimum temperature and humidity
conditions for this operation are a dry bulb temperature of
22.degree. to 26.degree. C. and a dew point temperature of
6.degree. to 9.degree. C. The molded tablets are collected into
trays and air dried at room temperature. Yield equals 1,400,000 to
1,500,000 tablets, each weighing approximately 34 mg. and labeled
to contain 1/200 grain (approximately 0.32 mg.) of nitroglycerin
per tablet; the acceptable variation is an average assay of 90
percent to 110 percent of the indicated potency.
The tablets prepared as described above are suitable for sublingual
administration and exhibit improved behavior on storage as
described in Example 1.
* * * * *